A grant from the National Institutes of Health will support continued research to develop products for soft tissue regeneration.
FesariusTherapeutics, Inc. announced they have been awarded $1.83 million to further fund the research of their Advanced Dermal Regeneration Scaffold for Reconstructive Surgery. The award from the National Institutes of Health (NIH) will support the company’s development of products beyond their flagship product, DermiSphere dermal template.1
DermiSphere provides affordable treatment for full thickness skin loss in cases such as burns, trauma, surgery, and chronic wounds. The dermal template can be applied simultaneously with a split thickness skin graft, restoring the dermal layer of the skin and eliminating the need for a second surgery, which is necessary in the current standard of care. Using DermiSphere can help by decreasing pain, morbidity, scarring, and cost.
DermiSphere is made of, “a novel biodegradable collagen microarchitecture that promotes native collagen deposition and rapid, robust vascularization to enable the viability of the skin graft.”1
"We are honored and excited to receive this prestigious grant from the NIH, which further validates our innovative technology and supports our mission to bring DermiSphere to the market," said Yulia Sapir-Lekhovitser, chief scientific officer of FesariusTherapeutics in a news release. "We believe that DermiSphere has the potential to revolutionize the treatment of full thickness skin loss and improve the quality of life for millions of patients worldwide."
The initial DermiSphere template is currently in biocompatibility studies required to support their US Food and Drug Administration (FDA) 510K submission this year. FesariusTherapeutics plans to begin early commercialization of their wound care technology in 2024. The NIH grant will support further development of alternate formulations of DermiSphere, allowing the technology to be used in adjacent advanced wound care and other soft tissue regeneration applications.
"This is the third NIH research award Fesarius has received to date and represents nearly $4 Million of non-dilutive grant funding for the company and its novel technology. It is very rewarding to see the tremendous work our team has conducted continue to receive peer recognition from such a prestigious institute as the NIH," said Tom Roueche, president and CEO of Fesarius.